Efficacy and Safety of TAH Combination in Comparison With Telmisartan/Amlodipine Combination for Essential Hypertension Patients

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It plans to enroll 300 participants.

Also called NCT02738632

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; double masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 300 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT02738632
Other papers using this trial's data
  • Efficacy and Tolerability of Telmisartan/Amlodipine + Hydrochlorothiazide Versus Telmisartan/Amlodipine Combination Therapy for Essential Hypertension Uncontrolled With Telmisartan/Amlodipine: The Phase III, Multicenter, Randomized, Double-blind TAHYTI Study Clinical therapeutics, 2018-01 DOI, PubMed 29248384

Courtesy of the U.S. National Library of Medicine.

Start date
(registry gives no type) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
South Korea (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT02738632. Randomized; double masking; primary purpose treatment. Start 2015-05 (registry gives no type); primary completion 2016-08 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Efficacy and Safety of TAH Combination in Comparison With Telmisartan/Amlodipine Combination for Essential Hypertension Patients
Condition
Essential Hypertension
Intervention (Drug)
Telmisartan/Amlodipine+Hydrochlorothiazide
Intervention (Drug)
Telmisartan/Amlodipine
Intervention (Drug)
Placebo for Hydrochlorothiazide
Lead sponsor
IlDong Pharmaceutical Co Ltd (class: industry)

Record details

Record id
cardio:ct-nct02738632
Content hash
6603a278f607b5a37f618f3a1c3669ad9fc3291a37fea4d5ad0d4ee6114a114c